参考文献

[1]张薇,许吉,邓宏勇.国际医学证据分级与推荐体系发展及现状.中国循证医学杂志, 2019,19(11): 1373-1378.

[2] Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence. OCEBM Levels of Evidence Working Group, 2011. [2023-01-21].http://www.cebm.net/index.aspx?o=5653.

[3] SIVAPALAN P, LAPPERRE T S, JANNER J, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre,randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med, 2019, 7(8): 699-709.

[4] GU D, HE J, DUAN X, et al. Body weight and mortality among men and women in China.JAMA, 2006, 295(7): 776-783.

[5]刘锦钰，赵琼姝，袁静，等.临床研究豁免知情同意的情形分析与探讨.中国医学伦理学,2019, 32(10): 1243-1246.

[6]詹思延.临床流行病学. 2版.北京：人民卫生出版社，2015.

[7]彭晓霞，方向华.循证医学与临床研究.北京：人民卫生出版社，2019.